What are the treatment options for acute myeloid leukaemia?

Acute myeloid leukaemia, or AML, affects immature cells that should develop into blood cells. Because it can change quickly, a haematology team usually plans treatment promptly. Initial treatment aims to clear visible leukaemia from the blood and marrow. Further treatment helps keep the disease controlled.

Chemotherapy acts on rapidly dividing leukaemia cells. Targeted therapy is matched to a feature found in some AML cells, so testing the leukaemia’s genes and proteins can influence the choice. An allogeneic stem cell transplant uses blood-forming cells from a donor after preparative treatment. It may be discussed when AML has features that make relapse more concerning or when the response is not sufficient.

Ask whether the team has tested the leukaemia for changes that can guide targeted treatment. Review heart, kidney, liver and lung health, because these checks help shape a safe plan. Discuss a central line, transfusions, infection prevention and fertility preservation before treatment begins. Tell the team about every medicine, supplement and recent infection. Regular blood tests and marrow assessments help show how AML is responding.

Call the treatment team urgently for fever, shaking chills, worsening breathlessness, new confusion, severe headache, black stools or bleeding that continues. Get emergency help for chest pain, collapse, a seizure or sudden trouble speaking. AML and its treatments can reduce healthy blood cells, so infection or bleeding symptoms need prompt assessment.

What do my AML genetic and cell tests show? Is a targeted medicine suitable? How will you check remission? When would a donor transplant be considered? What support will I receive for infections, transfusions, nutrition and side effects?